WASHINGTON, Dec 20 (Reuters) - Genentech Inc has resolved a dispute with doctors over the use of its cancer drug Avastin, a much less costly alternative to the biotech company's Lucentis for macular ...
Fatal side effects were 1.5 times more frequent among patients on Avastin plus chemotherapy than among those getting chemotherapy alone.The highest risk was seen in patients with prostate and lung ...
NEW YORK, Oct 31 (Reuters) - Biotechnology company Genentech Inc is delaying a plan that would make it harder to repackage its Avastin cancer drug as an inexpensive treatment for eye disease. Earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results